Drug
Bucillamine
Bucillamine is a pharmaceutical drug with 5 clinical trials. Historical success rate of 66.7%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
66.7%
Based on 2 completed trials
Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Terminated
1(20%)
Phase Distribution
Ph phase_4
1
20%
Ph phase_3
2
40%
Ph phase_2
2
40%
Phase Distribution
0
Early Stage
2
Mid Stage
3
Late Stage
Phase Distribution5 total trials
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
2(40.0%)
Phase 4Post-market surveillance
1(20.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(2)
Terminated(1)
Other(2)
Detailed Status
unknown2
Completed2
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
66.7%
Most Advanced
Phase 4
Trials by Phase
Phase 22 (40.0%)
Phase 32 (40.0%)
Phase 41 (20.0%)
Trials by Status
unknown240%
terminated120%
completed240%
Recent Activity
0 active trials
Showing 5 of 5
terminatedphase_3
Bucillamine in Treatment of Patients With COVID-19
NCT04504734
completedphase_3
A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)
NCT02373202
unknownphase_2
Bucillamine Phase 2 Trial in Patients With Cystinuria
NCT02942420
completedphase_2
Bucillamine for the Treatment of Acute Gout Flare in Subjects With Moderate to Severe Gout
NCT02330796
unknownphase_4
Bucillamine Study of Holding Remission After Infliximab Dose-off
NCT00716248
Clinical Trials (5)
Showing 5 of 5 trials
NCT04504734Phase 3
Bucillamine in Treatment of Patients With COVID-19
NCT02373202Phase 3
A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)
NCT02942420Phase 2
Bucillamine Phase 2 Trial in Patients With Cystinuria
NCT02330796Phase 2
Bucillamine for the Treatment of Acute Gout Flare in Subjects With Moderate to Severe Gout
NCT00716248Phase 4
Bucillamine Study of Holding Remission After Infliximab Dose-off
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5